Semaglutide vs. Tirzepatide: 2025’s Leading GLP-1s Compared
In the race for the most effective GLP-1 treatment, Semaglutide and Tirzepatide lead the field in 2025. Both are powerful tools in managing obesity and type 2 diabetes, but key differences in formulation and performance may influence patient preference.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Brand Names | Ozempic, Wegovy | Mounjaro |
| Mechanism | GLP-1 Agonist | Dual GLP-1/GIP Agonist |
| Average Weight Loss | ~15% | ~22% |
| Injection Frequency | Weekly | Weekly |
According to recent clinical comparisons, Semaglutide offers reliable results, especially for patients focused on gradual improvements. However, Tirzepatide delivers faster, more pronounced outcomes due to its dual-action effect.
Not sure which GLP-1 is right for you? Explore our detailed guide here: Top GLP-1 Drugs for Diabetes and Obesity in 2025.